As it requested, the U.S. FDA got an earful April 25 as people with long COVID and their caregivers shared their experiences with the condition that has no approved, or even authorized, treatment and is not that well understood, given its range of symptoms that vary from person to person.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, Beigene, Bioinvent, Cantex, Dare, Maia, Promore, Sellas, Visus.
While the pandemic is nearing its end, Chinese officials are calling for the development of novel, multivalent COVID-19 vaccines as an essential task moving forward. To date, China has 17 COVID-19 vaccine products that have completed or are in phase III trials, according to the NMPA.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Direct, Everest, Finch, Keyuan Xinhua, Maxion, Nona, Shanghai, Sinopia.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Alzamend, Alzheon, Anixa, Arch, Autobahn, Biolinerx, Clearside, FSD, Lisata, Madrigal, Merus, Nova Mentis, Plus, Renovion, Sellas, Technoderma.
The latest U.S. FDA emergency use authorizations to fall by the wayside, as COVID-19 continues to evolve, are the ones for the first Moderna Inc. and Pfizer Inc.-Biontech SE’s mRNA vaccines.
Additional early-stage research and drug discovery news in brief, from: Dragonfly Therapeutics, Enanta Pharmaceuticals, Enanta Pharmaceuticals, Kura Oncology, Telix Pharmaceuticals, Tonix Pharmaceuticals.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astellas, Gilead, Mindmedicine, Minghui, Ocugen, Sunstone, Travere, Zenshine.
RSS
